Search
Botanix executive chairman Vince Ippolito was positive about the results, particularly the Australian data.

Botanix shares plunge on study results

Shares in Bentley-based medical cannabis company Botanix Pharmaceuticals have nearly halved, after it released the results of its clinical trial for acne treatment.

Login

(existing subscribers)

The password field is case sensitive.
Request new password

Add your comment

Share Price

Closing price for the last 90 trading days
Source: Morningstar

Top 10 Shareholders

Substantial shareholders as published in the annual report.
Source: Morningstar

Total Shareholder Return as at 31/10/19

1 year TSR5 year TSR
47thPharmAust145%-9%
174thBotanix Pharmaceuticals39%27%
608thNuheara-35%27%
662ndSpectur-44%
730 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Source: Morningstar

Share Transactions

18/07/19
$0 Issued
27/04/18
$19k Bought
27/04/18
$94k Sold
Total value as at the date of the transaction
Source: Morningstar

Revenue

92nd-Spectur$4.8m
93rd↑Botanix Pharmaceuticals$4.7m
95th↑Nuheara$4.5m
96th↑PharmAust$4.3m
197 listed industrial companies ranked by revenue.
Source: Morningstar

BNiQ Disclaimer